Clinical Trials Arena18h
Asceletis’ muscle-preserving weight loss therapy sustains 40-day half-life
The company’s weight loss therapy was able to sustain itself for up to 40 days in obese patients after a single injection.
News-Medical.Net22h
Gilead’s capsid revolution meets our capsid solutions: Sino Biological – Engineering the tools to outsmart HIV
Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir ...